Plaintiffs have brought claims against the makers of YAZ®, Yasmin® and Ocella®, for injuries ranging from internal organ damage (including gallbladder damage), to deep vein thrombosis (or blood clots), stroke, heart attack, myocardial infarction and pulmonary embolism.
As we have discussed in previous posts, studies have shown that the ingredients contained in YAZ®, Yasmin® and Ocella® have been linked to various forms of severe side-effects. Reportedly, these side-effects include: heart attack, stroke, deep vein thrombosis (also known as DVT or blood clots), internal organ damage (including gallbladder damage), myocardial infarction and pulmonary embolism. Recently, a large number of YAZ® lawsuits have been designated as Mass Tort or Multidistrict Litigation (MDL) cases.
As we have discussed in previous posts, studies have shown that the ingredients contained in YAZ®, Yasmin® and Ocella® have been linked to various forms of severe side-effects. Reportedly, these side-effects include: heart attack, stroke, deep vein thrombosis (also known as DVT or blood clots), internal organ damage (including gallbladder damage), myocardial infarction and pulmonary embolism. Recently, a large number of YAZ®, Yasmin® and Ocella® cases have been designated as Mass Tort or Multidistrict Litigation (MDL) cases.
Since the beginning of October 2009, over 350 YAZ®, Yasmin® and Ocella® cases from various jurisdictions throughout the country have been transferred to the MDL in the United States District Court for the Southern District of Illinois. On November 9, 2009, motions were filed to appoint Plaintiffs’ lead counsel and a Plaintiffs’ Steering Committee. The Court will hold a conference in the coming weeks to address the newly transferred cases and pending motions.
Studies have shown that the ingredients contained in YAZ®, Yasmin® and Ocella® (including the synthetic progestin, drospirenone), have been linked to various forms of internal organ damage (including gallbladder damage), as well as deep vein thrombosis, or blood clots. These blood clots can form in the deep veins of the legs, pelvis, or arms causing major discomfort. It has been found that, if the clot dislodges, it can lead to sudden, and many times fatal, stroke, heart attack, myocardial infarction or pulmonary embolism.
As we have discussed in previous posts, NuvaRing®, the combined contraceptive vaginal ring that is supposed to provide month-long birth control, is currently involved in a Multi-District Litigation (“MDL”) in the United States District Court for the Eastern District of Missouri. Recently, defendants filed numerous motions to dismiss certain plaintiff’s claims for failure to provide a timely or complete “Plaintiff Fact Sheet” (also known as a “PFS”). In pharmaceutical cases with Mass Tort or Multi-District Litigation designations, plaintiffs are required to submit a detailed PFS.
NuvaRing®, the combined contraceptive vaginal ring that is supposed to provide month-long birth control, is currently involved in a Multi-District Litigation (“MDL”) in the United States District Court for the Eastern District of Missouri. Plaintiffs have advanced claims that NuvaRing® is responsible for injuries in some individuals.
The Court recently denied a motion by Defendants to dismiss the Master Consolidated Complaint in the MDL. On August 17, 2009, Defendants filed a motion for certification of an interlocutory appeal. Defendants seek the Court’s permission to challenge the denial of Defendants’ motion to dismiss. In plain English, this means that Defendants are attempting to appeal in the middle of the ongoing case.
In a recent blog post, it was reported that NuvaRing® plaintiffs had filed a master consolidated complaint in order to supplement the complaints in the individual NuvaRing® litigation cases. On May 19, 2009, the Court dismissed the class action claims in the Master Consolidated Complaint. The Court noted that such claims are usually not appropriate for personal injury lawsuits based on pharmaceuticals.
NuvaRing®, the once-a-month combined contraceptive vaginal ring which is supposed to provide month-long birth control, is currently involved in a Multi-District Litigation (“MDL”) in the United States District Court for the Eastern District of Missouri based on claims that NuvaRing® is responsible for injuries in some individuals.
